Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 7/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7545079 | 0.76 | NPY1R (0.73) | NPY1RCRHR1KMT2APOLBMEN1 | |
| SCHEMBL1593495 | 0.76 | NPY1R (0.52) | NPY1RCRHR1KMT2AMEN1 | |
| SCHEMBL7041916 | 0.74 | NPY1R (0.51) | NPY1RCRHR1 | |
| SCHEMBL1593291 | 0.74 | NPY1R (0.47) | NPY1RCRHR1 | |
| SCHEMBL1594404 | 0.73 | NPY1R (0.49) | NPY1RCRHR1 | |
| SCHEMBL1593501 | 0.72 | NPY1R (0.47) | NPY1RCRHR1 | |
| SCHEMBL6520712 | 0.72 | NPY1R (0.49) | NPY1RCRHR1 | |
| SCHEMBL1593564 | 0.72 | CYP1A2 (0.48) | NPY1RCRHR1 | |
| SCHEMBL1594245 | 0.72 | NPY1R (0.47) | NPY1RCRHR1 | |
| SCHEMBL1593270 | 0.70 | NPY1R (0.56) | NPY1RCRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NEUROGEN CORPORATION (US) | 2003-04-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069246-A1 | Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo [1,5-a]-1,3,5-triazines | NPY1R, NPY5R, NPY2R | NPY1R 1/4885CRHR1 15/4885KMT2A 2998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.